

Enquiries:

Stock queries:

Ms Babalwa Melitafa

E-mail: Babalwa.Melitafa@health.gov.za

Clinical queries:

Essential Drugs Programme

E-mail: SAEDP@health.gov.za

NOTICE:

- **PUBLICATION OF THE 2024 EDITIONS OF THE PRIMARY HEALTHCARE (PHC) 8TH EDITION AND THE ADULT HOSPITAL LEVEL (AHL) 6TH EDITION STANDARD TREATMENT GUIDELINES (STGs) AND ESSENTIAL MEDICINES LIST (EML);**
- **ERRATUM TO THE PUBLISHED 2024 INDIVIDUAL PHC CHAPTER 11: HIV AND AIDS AND AHL CHAPTER 1: ALIMENTARY TRACT STGs AND EML.**

Kindly note that the complete editions of the 2024 PHC (8th edition) and the AHL (6th edition) STGs and EMLs are now published on the National Department of Health website at: <https://www.health.gov.za/nhi-edp-stgs-eml/>. The complete editions replace the PHC (2020) and AHL (2019) versions.

Additionally, please note the corrections to the individually published versions of the PHC Chapter 11: HIV and AIDS and the AHL Chapter 1: Alimentary Tract STGs and EML in the table below which are now reflected in the 2024 PHC 8th and the AHL 6th complete editions.

The eGFR monitoring intervals for patients on tenofovir disoproxil fumarate (TDF) has been corrected in the above-mentioned chapters as follows:

PHC Chapter 11: HIV AND AIDS <i>Section: 11.4 HIV AND KIDNEY DISEASE</i> Screening for renal disease in HIV	
<u>Previous text</u>	<u>Amended text</u>
Monitor creatinine/eGFR on initiation and at months 3, 6, 12 and then 12 monthly for patients receiving tenofovir.	<ul style="list-style-type: none"> • In patients receiving tenofovir, monitor creatinine/eGFR at month 3, month 10, and every 12 months thereafter. Align with VL monitoring schedule.


- PUBLICATION OF THE 2024 EDITIONS OF THE PRIMARY HEALTHCARE (PHC) 8TH EDITION AND THE ADULT HOSPITAL LEVEL (AHL) 6TH EDITION STANDARD TREATMENT GUIDELINES (STGs) AND ESSENTIAL MEDICINES LIST (EML);
- ERRATUM TO THE PUBLISHED 2024 INDIVIDUAL PHC CHAPTER 11: HIV AND AIDS AND AHL CHAPTER 1: ALIMENTARY TRACT STGs AND EML.

AHL Chapter 1: Alimentary Tract <i>Section: 1.2.4.2 HEPATITIS B, CHRONIC (NON-HIV COINFECTION)</i> Monitoring whilst on tenofovir			
<u>Previous text</u>		<u>Amended text</u>	
Serum creatinine	<u>All patients:</u> Baseline <u>Patients on TDF:</u> Week 4, then 3 months, 6 months, and 12 months after initiation; then, every 12 months thereafter.	Serum creatinine	<u>All patients:</u> Baseline <u>Patients on TDF:</u> Month 3, month 10, and every 12 months thereafter.

Erratum dissemination

Provinces and Healthcare facilities are requested to distribute and communicate this information in consultation with the Pharmaceutical and Therapeutics Committees and all other relevant stakeholders.

Kind regards



MS K JAMALOODIEN
CHIEF DIRECTOR: SECTOR WIDE PROCUREMENT
DATE: 29 July